Johnson & Johnson

• Novo Nordisk halted two late-stage Phase 3 ziltivekimab trials due to futility. • Positive STEP Young trial results for semaglutide failed to lift sentiment. • Technical indicators show a MACD sell signal and oversold Williams %R.

• Bristol-Myers Squibb faced profit-taking despite positive Phase 2 trial results for arlocabtagene autoleucel. • Investors reacted cautiously due to unspecified regulatory timelines and recent clinical trial enrollment pauses. • The company reports $48.19B in annual revenue and maintains solid financial operating metrics.

• Vertex shares faced volatility and profit-taking after rallying near their 52-week high. • The Crinetics acquisition integration will not be non-GAAP accretive until 2029. • Technical indicators show a neutral MACD, neutral RSI, and oversold Williams %R.

• Gilead pulled back due to profit-taking following a sustained multi-month rally. • Strong second-quarter revenue was driven by flagship HIV and Trodelvy franchises. • Analysts maintain Buy ratings with an average price target of $157.79.

• Novartis trial failure for pelacarsen increased clinical uncertainty for Amgen's competing olpasiran. • BMO Capital downgraded Amgen from Outperform to Market Perform amid valuation concerns. • Technical indicators show Amgen's RSI at 40.256 and Williams %R at 97.857.

• Novartis shares dropped after the Phase III HARBOR trial for del-desiran failed. • The pelacarsen cardiovascular trial also missed its primary endpoint of reducing events. • Multiple pipeline setbacks intensified investor scrutiny and raised structural growth risks.